1653 – Amendment to eligibility criteria for tisagenlecleucel for treatment of relapsed or refractory diffuse large B-cell lymphoma - removal of the requirement for patients to be “CD19-positive”

Page last updated: 15 February 2021

Application Detail

Description of Medical Service

Tisagenlecleucel is an autologous, murine anti-CD19 Chimeric Antigen Receptor T cell therapeutic process, involving harvesting, modifying, expanding and re-infusing a patient's own immune T-cells, to target and destroy certain cancerous cells.

Description of Medical Condition

Diffuse Large B-Cell Lymphoma is an aggressive and common subtype of Non-Hodgkin Lymphoma.

Reason for Application

Request to amend the eligibility criteria to remove the requirement for patients to be “CD19-positive”.

Medical Service Type

Hybrid health technology

Previous Application Number/s

1519
1519.1

Associated Documentation

Public Summary Document

Public Summary Document (PDF 318 KB)
Public Summary Document (Word 73 KB)

Meetings for this Application

PASC

Expedited Bypassing PASC

ESC

Expedited Bypassing ESC

MSAC

26-27 November 2020